New guidelines expand management options for hereditary hemorrhagic telangiectasia

Reuters Health - 09/09/2020 - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert panel behind the Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines extended its recommendations for epistaxis treatment to include oral tranexamic acid, ablative therapies, systemic antiangiogenic agents and surgical approaches when epistaxis does not respond to moisturizing topical therapies. Patients with suspected HHT-related GI bleeding should first undergo esophagogastroduodenoscopy; if this does not reveal significant HHT-related telangiectasia, capsule endoscopy should be considered, say Dr. Marie E. Faughnan of St. Michael's Hospital, in Toronto, Canada and colleagues. Treatment for HHT-related GI bleeding should depend on the severity of the bleeding and its response to oral iron ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 September, 202016 September, 2020